Back to discover
Disease

postencephalitic Parkinson's disease

Late-stage therapeutic development

Also known as postencephalitic Parkinsonism, postencephalitic parkinsonism.

24
Clinical trials
1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones15View all 15
Results posted 1
Results expected 5
Recently completed 5
Other updates 3
+7 more in the activity timeline below
Activity timeline15

Clinical trials

17 sponsors · 4 new · 5 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease

Phase 3 · Recruiting · BlueRock Therapeutics

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Phase 3 · Recruiting · Hoffmann-La Roche

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

Phase 3 · Recruiting · University Hospital Tuebingen

Edmond J Safra, Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) - a Multi-arm Multi-stage Platform Trial for Potential Disease Modifying Approaches.

Phase 3 · Recruiting · University College, London

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

Phase 3 · Recruiting · Radboud University Medical Center

An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease

Phase 2/3 · Recruiting · Annovis Bio Inc.
Recruiting

exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease

Phase 3 · Recruiting · BlueRock Therapeutics

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Phase 3 · Recruiting · Hoffmann-La Roche

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

Phase 3 · Recruiting · University Hospital Tuebingen

Edmond J Safra, Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) - a Multi-arm Multi-stage Platform Trial for Potential Disease Modifying Approaches.

Phase 3 · Recruiting · University College, London

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

Phase 3 · Recruiting · Radboud University Medical Center

An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease

Phase 2/3 · Recruiting · Annovis Bio Inc.
Recently completed

An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease

Phase 3 · Completed · AbbVie

TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease

Phase 4 · Completed · California Pacific Medical Center Research Institute

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

Phase 3 · Completed · Tasly Pharmaceutical Group Co., Ltd

Oxyhydrogen Nanobubble Infusion as a Complementary Therapy in Patients With Parkinsonism

Phase 2/3 · Completed · dr. Siti Nurlaela, SpN

A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

Phase 4 · Completed · Second Affiliated Hospital of Soochow University

Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia

Phase 4 · Completed · Mayo Clinic

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

DDC0.38

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Aromatic-L-amino-acid decarboxylasevia DDC0.38

Reference

Authoritative identity, definition & identifiers.

Synonyms

postencephalitic Parkinsonism, postencephalitic parkinsonism

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.